Tuesday, November 17, 2026
CN
  • About
  • Advertise
  • Careers
  • Contact
Money Compass
  • Home
  • Financial News
  • Investment News
  • Other News
    • Bursa News
    • Government News
    • Listing Companies News
    • Oversea Financial & Investment News
  • Interviews
    • Features Interviews
    • Corporate Interviews
  • Financial & Investment Articles
  • PR Newswire
  • Login
No Result
View All Result
Money Compass
Home PR Newswire

Daewoong Pharmaceutical Presents Phase 1 Clinical Trial Data for New Autoimmune Disease Drug ‘Plodicitinib’ at ACR Convergence 2026

Money Compass by Money Compass
November 17, 2026
in PR Newswire
0
Daewoong Pharmaceutical Presents Phase 1 Clinical Trial Data for New Autoimmune Disease Drug ‘Plodicitinib’ at ACR Convergence 2026
1
SHARES
100
VIEWS
Share on FacebookShare on Twitter
  • Presented at the American College of Rheumatology (ACR) conference… Confirmed over 90% BTK and ITK target coverage, securing early pharmacodynamic evidence
  • Distinctive mechanism that simultaneously modulates T cells and B cells… Potential for development across a wide range of autoimmune diseases
  • Multiple-ascending dose study currently underway… Phase 1 clinical trial completion targeted for the first quarter of 2027

SEOUL, South Korea and ORLANDO, Fla., Nov. 17, 2026 /PRNewswire/ — Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Changjae Lee) announced that it presented data from the Phase 1 clinical trial of its new drug candidate for autoimmune diseases, ‘Plodicitinib(DWP212525)’, at the ‘American College of Rheumatology (ACR) Convergence 2026’ held on November 9 (local time) in Orlando, Florida.

Hyemi Park, a Program Lead (PL) on Clinical Development Center at Daewoong Pharmaceutical, is presenting Phase 1 clinical trial results for the new autoimmune disease drug candidate ‘Plodicitinib(DWP212525)’ at ACR Convergence 2026.
Hyemi Park, a Program Lead (PL) on Clinical Development Center at Daewoong Pharmaceutical, is presenting Phase 1 clinical trial results for the new autoimmune disease drug candidate ‘Plodicitinib(DWP212525)’ at ACR Convergence 2026.

Related posts

TriNetX Names Carnell Elliott Chief Commercial Officer

TriNetX Names Carnell Elliott Chief Commercial Officer

November 17, 2026
THE HONG KONG MANAGEMENT ASSOCIATION 2026 HKMA/ HKJC ANNUAL CONFERENCE ON “Capitalizing on Hong Kong’s Strategic Edge in a Changing World”

THE HONG KONG MANAGEMENT ASSOCIATION 2026 HKMA/ HKJC ANNUAL CONFERENCE ON “Capitalizing on Hong Kong’s Strategic Edge in a Changing World”

November 17, 2026

Plodicitinib is an oral new drug candidate currently being developed by Daewoong Pharmaceutical as a treatment for autoimmune and inflammatory diseases. By selectively inhibiting JAK3—which regulates the activity and function of immune cells—as well as ITK and BTK, which are involved in the activation of T cells and B cells (key immune cells), it modulates the excessively activated immune response in patients with autoimmune diseases to an appropriate level.

Unlike many existing treatments for inflammatory and autoimmune diseases, which are limited to inhibiting T cells or B cells, Plodicitinib has a distinct mechanism of action: it simultaneously targets JAK3, ITK, and BTK, enabling it to broadly modulate immune responses in which T cells and B cells are involved in a complex manner. Based on this, it is expected to have potential applications in various autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome.

At this conference, results from the first-in-human Phase 1 single-ascending dose (SAD) clinical trial of Plodicitinib, conducted in 44 healthy adults, were presented. Analysis revealed that the maximum target occupancy for both BTK and ITK—the primary targets—exceeded 90%. Target occupancy is an indicator of the extent to which a drug binds to its target protein; these results provide initial pharmacodynamic evidence of Plodicitinib target engagement.

Pharmacokinetic(PK) evaluations showed that drug exposure in the body increased with higher doses. Furthermore, the safety evaluation revealed no serious adverse events during the study period, and all treatment-emergent adverse events were mild. No significant differences in the incidence of adverse events were observed even as the dose was increased.

Following the completion of the SAD study, Daewoong Pharmaceutical is currently conducting a multiple-ascending dose (MAD) study and aims to complete Phase 1 clinical trials in the first quarter of 2027.

Professor Seunghwan Lee of the Department of Clinical Pharmacology at Seoul National University Hospital, who is leading this clinical trial, stated, “No significant safety issues, such as serious adverse events, were identified in the SAD study conducted in healthy adults,” adding, “Considering the safety results observed in the SAD study, we expect favorable tolerability in the MAD study as well.”

Seongsoo Park, CEO of Daewoong Pharmaceutical, remarked, “The high target occupancy rate observed for both BTK and ITK in this SAD study represents a meaningful initial finding supporting further clinical development.” He added, “We will continue to gather clinical data through the ongoing MAD study and explore the development potential of Plodicitinib across various autoimmune diseases and pursue global development opportunities.”

​ 

Previous Post

Isomorphic Labs announces $5 Billion Series C funding

Next Post

THE HONG KONG MANAGEMENT ASSOCIATION 2026 HKMA/ HKJC ANNUAL CONFERENCE ON “Capitalizing on Hong Kong’s Strategic Edge in a Changing World”

Next Post
THE HONG KONG MANAGEMENT ASSOCIATION 2026 HKMA/ HKJC ANNUAL CONFERENCE ON “Capitalizing on Hong Kong’s Strategic Edge in a Changing World”

THE HONG KONG MANAGEMENT ASSOCIATION 2026 HKMA/ HKJC ANNUAL CONFERENCE ON "Capitalizing on Hong Kong's Strategic Edge in a Changing World"

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

BROWSE BY CATEGORIES

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire

BROWSE BY TOPICS

2018 League Balinese Culture Bali United Budget Travel business Champions League Chopper Bike Doctor Terawan industrial Istana Negara Malaysia Market Stories National Exam net zero emissions targets 2025 Renewable energy Visit Bali

Recent News

  • TriNetX Names Carnell Elliott Chief Commercial Officer
  • THE HONG KONG MANAGEMENT ASSOCIATION 2026 HKMA/ HKJC ANNUAL CONFERENCE ON “Capitalizing on Hong Kong’s Strategic Edge in a Changing World”
  • Trend Technologies Partners with Novo Tellus to Accelerate Growth

Category

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire
  • About
  • Advertise
  • Careers
  • Contact

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Features Interviews
  • Government News
  • Financial News
  • Investment News
  • Listing Companies News
  • Corporate Interviews
  • Bursa News
  • Financial & Investment Articles
  • Oversea Financial & Investment News

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved